Dallas, Texas 08/01/2013 (Financialstrend) – Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) is concentrated in development of drugs for the treatment of gastrointestinal infections and related diseases. CEM-101 (OP-1068) and OPT-822/821 are the company’s two principal products. There had been an inquiry on the company related to whether the Optimer directors are breaking their fiduciary duties by failing to appropriately shop the Company and increase the shareholder value. Under the conditions of the agreement made for the acquisition, Optimer shareholders will be eligible to receive $10.75 per share in cash for each share of the company’s common stock. In addition to the upfront cash payment, each stockholder of this company will get a Casual Value Right, that is related to be publicly traded companies, entitling the holder to get additional one-time cash payment of up to $5.00 for each share they hold if certain net sales limits of DIFICID® are also succeeded. A target price is set at $16.00 per share for the company’s common stock. The company is concentrated on producing and commercializing hospital specialty products. The company’s product OPT-822/821 is used for the treatment of metastatic breast cancer. Food and Drug Administration of US had sanctioned DIFICID for the treatment of Clostridium difficile-associated diarrhea.
Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) had presented loss of 5.87% with the trading on Wednesday and had thereby closed at $12.51 per share. While the stock opened at $12.43 per share, there had been fluctuations in the intraday prices ranging between $12.38 and $12.66 per share during the day. The 52 week low price for the stock is presently at $8.64 and 52 week high price is at $16.80 per share. There are a total 698.00 million shares in the market valuing to a market cap of $609.50 million. The stock witnessed around 13.58 million shares being exchanged hands on Wednesday while the average level of trading is at 925,280 shares a day.